Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492 is registered in ClinicalTrials.gov with Human Genome Sciences Inc., a GSK Company as lead sponsor.

NCT NCT01597492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01597492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Effect of BENLYSTA™ (Belimumab; HGS1006) on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2012
Completion date
September 24, 2015
Enrollment
79 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus